NOVEL BIOMARKER AS THERAPEUTIC TARGET IN LUNG CANCER

摘要

The present invention relates to a method for prognosis of the progression of the disease of a subject suffering from adenocarcinoma of the lung, which comprises either measuring expression of the Rho B gene or measuring the number of copies of the Rho B gene in a sample taken from said subject suffering from adenocarcinoma of the lung, characterized in that detection of the overexpression or increase in the number of copies of the Rho B gene as compared with expression or the number of copies of same gene in a control sample is indicative of the risk of metastasis or reappearance or recurrence of neoplastic activity. The present invention further provides screening methods for drugs that are active against adenocarcinoma of the lung with a view to determining the efficacy of a therapeutic treatment model in a subject suffering from adenocarcinoma of the lung and also drugs that inhibit overexpression of the Rho B gene, for use as a drug or for use in the treatment of non-small-cell lung cancers (NSCLC).